Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
AnaptysBio, Inc. - Common Stock
(NQ:
ANAB
)
47.54
+0.21 (+0.44%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AnaptysBio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
ANAPTYBIO INC (NASDAQ:ANAB) Offers High-Growth Momentum and a Bullish Technical Setup
↗
January 23, 2026
Via
Chartmill
ANAPTYSBIO INC (NASDAQ:ANAB) Shows Minervini Trend Template and High-Growth Momentum Alignment
↗
January 17, 2026
Via
Chartmill
What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally
↗
January 11, 2026
This biotech innovator in antibody therapies just reported a significant insider sale amid a period of strong share price gains.
Via
The Motley Fool
Topics
Regulatory Compliance
What Investors Should Know About a $163K AnaptysBio Insider Sale
↗
January 11, 2026
This clinical-stage biotech specializing in antibody therapeutics reported a notable insider sale amid ongoing development and partnerships.
Via
The Motley Fool
Topics
Intellectual Property
Regulatory Compliance
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
January 08, 2026
From
AnaptysBio, Inc.
Via
GlobeNewswire
ANAB Stock Falls After It Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal
↗
November 21, 2025
The dispute centers around Tesaro’s participation in PD-1 trials.
Via
Stocktwits
Topics
Lawsuit
AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level
↗
September 30, 2025
Via
Stocktwits
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From
AnaptysBio, Inc.
Via
GlobeNewswire
AnaptysBio Inc (NASDAQ:ANAB) Meets Minervini Trend Template with High-Growth Momentum
↗
December 20, 2025
AnaptysBio (ANAB) meets the Minervini Trend Template, showing a powerful technical uptrend backed by accelerating earnings and revenue growth momentum.
Via
Chartmill
Anaptys Announces Participation in December Investor Conferences
November 25, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
AnaptysBio Inc (NASDAQ:ANAB) Screens as a High-Growth Momentum Leader
↗
November 22, 2025
AnaptysBio (ANAB) is a high-growth biotech stock with a strong technical uptrend, surging revenue, and impressive relative strength.
Via
Chartmill
Anaptys Announces $100 Million Stock Repurchase Plan
November 21, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
November 21, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
ANAPTYSBIO INC (NASDAQ:ANAB) Shows High-Growth Momentum and Positive Technical Setup
↗
November 13, 2025
ANAB stock shows explosive revenue growth and strong technical setup, making it a top momentum pick for biotech investors.
Via
Chartmill
AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study
↗
November 10, 2025
AnaptysBio ends its ulcerative colitis trial after rosnilimab misses key goals, focusing resources on rheumatoid arthritis and future programs.
Via
Benzinga
Why AnaptysBio Stock Plummeted, Reversing A 70% Monthlong Run
↗
November 10, 2025
The company was working on a treatment for ulcerative colitis, using a relatively different approach.
Via
Investor's Business Daily
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
November 10, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Participation in November Investor Conferences
November 04, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
November 04, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
October 29, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
October 13, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
Wall Street Climbs Despite Shutdown Risk — Pfizer and CoreWeave Shine Bright
↗
October 01, 2025
Markets closed in the green on Tuesday, undeterred by the looming U.S. government shutdown. Pfizer surged nearly 7% on a political deal, while CoreWeave soared after signing a multibillion-dollar AI...
Via
Chartmill
Topics
Artificial Intelligence
Here are the top movers in Tuesday's session.
↗
September 30, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via
Chartmill
AnaptysBio Charts Path To Split Into Two Public Companies By 2026
↗
September 30, 2025
AnaptysBio plans to separate into Royalty Management Co. and Biopharma Co. by 2026, with each positioned for growth in distinct market areas.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
September 30, 2025
Via
Benzinga
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday
↗
September 30, 2025
Via
Benzinga
Tuesday's session: gap up and gap down stocks
↗
September 30, 2025
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via
Chartmill
12 Health Care Stocks Moving In Monday's After-Market Session
↗
September 29, 2025
Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's market cap stands at $2.2 million.
Via
Benzinga
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
September 29, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
September 29, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
